[Efficacy and safety of valdoxan in patients with irritable bowel syndrome].
To evaluate the efficacy and safety of the antidepressant valdoxan in irritable bowel syndrome (IBS) with comorbid mild and moderate depression. Twenty-eight patients with IBS and depression without psychotic symptoms were studied using clinical examination and psychometric scales. A significant reduction in psychopathological symptoms, along with the improvement of health status, was recorded for most patients treated with valdoxan (25-50 mg/night) in the end of the 1st week. Valdoxan has a good tolerability and safety profile, does not exert any negative effect on the IBS course and provides a high level of compliance.